TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16547381
Drug: Ibuprofen (IBU)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBU) 10‐5‐5 mg/kg
Study: 9359536
Drug: bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (200 mg 3 times daily)
Study: 8201912
Drug: Voltaren sustained
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren sustained release, 100 mg once a day
Study: 8201912
Drug: Nodo regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nodo regular formulation, 200 mg once a day
Study: 3018564
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of intramuscular iodized oil
Study: 20426866
Drug: Maintenance Cognitive
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Cognitive Stimulation Therapy (CST) for 24 weeks after initial CST for 7 weeks
Study: 20426866
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) for 7 weeks followed by treatment as usual for 24 weeks
Study: 18617301
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg twice daily for eGFR 30 to 60 mL/min/1.73 m² or once daily for eGFR 10 to 29 mL/min/1.73 m²)
Study: 11921456
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI) 300 mg b.i.d. for 24 weeks
Study: 1741572
Drug: Calcium, Parathyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium, Parathyroid hormone, Osteocalcine
Study: 1741572
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration over 3 years
Study: 30920874
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injected on the buccal aspect of supporting teeth
Study: 21098317
Drug: Ferric gluconate
Normalized name: Ferric Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric gluconate 187.5 mg IV every 3 weeks
Study: 21098317
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily ferrous sulfate 325 mg
Study: 19675481
Drug: Contrast Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast Water Therapy (C(T)WT)
Study: 15017207
Drug: Sextant biopsies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sextant biopsies recommended when total PSA was 3 ng/ml or greater at screening rounds 1 and 2, and 2.54 ng/ml or greater at subsequent screening rounds.
Study: 9487256
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate treatment
Study: 7961544
Drug: Newer antidepressants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antidepressants (SSRIs, venlafaxine, bupropion)
Study: 7961544
Drug: Older tricyclic
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older tricyclic antidepressants
Study: 31009695
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy targeting an SpO2 of 90–94% (intervention)
Study: 31009695
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy targeting an SpO2 of 98–100% (control)
Study: 29325319
Drug: Half-dose spectral
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose spectral CT based on GSI Assist with 50% ASIR (group A)
Study: 29325319
Drug: Half-dose spectral
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose spectral CT (group A)
Study: 25410205
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of Peru-15 pCTB vaccine at dosages of 1 ×10(7), 1 ×10(8), 1 ×10(9), and 1 ×10(10) CFU
Study: 25410205
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of Peru-15 pCTB vaccine
Study: 30169323
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition
Study: 18955454
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² every 3 weeks plus lapatinib 1,500 mg/d
Study: 10758783
Drug: Methylprednisolon‐ratiopharm 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolon‐ratiopharm 8 mg tablets (test preparation)
Study: 10758783
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation 8 mg tablets (control)
Study: 30260990
Drug: gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (1200 mg/day)
Study: 7856526
Drug: simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (20 mg/day)
Study: 3976757
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate, 250 mg by intramuscular injection once a week
Study: 22622851
Drug: Vaginal combination
Normalized name: CVS Miconazole 3 Vaginal Combination Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal combination therapy including 500 mg metronidazole and 100 mg miconazole nitrate two times a day for 7 days
Study: 22622851
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative vaginal therapy)
Study: 10619824
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (500 microg twice daily)
Study: 6712851
Drug: Naloxone 0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.006 mg kg‐1 5 min before induction of anaesthesia
Study: 27836715
Drug: Improvisation Theater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisation Theater (IT) program, 60 min sessions weekly for 12 weeks
Study: 26581787
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (once- or twice-weekly)
Study: 26581787
Drug: Balance-and-toning (twice-weekly)
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance-and-toning (twice-weekly)
Study: 23886521
Drug: Lidocaine 1mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1mg/mL
Study: 23579103
Drug: Lidocaine 10mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10mg/mL
Study: 19382010
Drug: Paroxetine controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled release (CR) 12.5-62.5 mg/day
Study: 17005075
Drug: Quyu Xiaoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quyu Xiaoban Capsule (QYXBC) for 10 months
Study: 12725259
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in addition to antisnake venom (ASV)
Study: 7909642
Drug: Prehydration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehydration with balanced electrolyte solution
Study: 26868123
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU D3 daily for 6 months
Study: 26868123
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU D3 daily for 6 months
Study: 25775024
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy in combination with Ofatumumab (CHOP-O)
Study: 25775024
Drug: Ofatumumab maintenance
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab maintenance therapy
Study: 23090424
Drug: Intermittent drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent drain clamping with injection of diluted epinephrine solution (Group I)
Study: 23090424
Drug: Nonclamping without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonclamping without injection of diluted epinephrine solution (Group II)
Study: 23488876
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg alcohol
Study: 11104118
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg alcohol
Study: 1586604
Drug: Chemotherapy (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide 1,000 mg m‐2 i.v., doxorubicin 50 mg m‐2 i.v., vincristine 1.4 mg m‐2 i.v., and prednisolone 40 mg orally for 5 days, given 3 weekly for four cycles) + Radiotherapy (CHOP + RT)
Study: 1586604
Drug: Chemotherapy (CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHOP + RT)
Study: 2872569
Drug: L-363,586 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-363,586 (10 micrograms/hr)
Study: 27570088
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1000 mg single dose)
Study: 24170101
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen treatment for 3 weeks
Study: 22904179
Drug: GH 2
Normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 2 mg/m(2) · d during puberty
Study: 21275161
Drug: Three-step acupuncture
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step acupuncture (TSA) combined with small dosage antipsychotic
Study: 21275161
Drug: Full-dose antipsychotic
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose antipsychotic
Study: 3846198
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment with amoxicillin (3.0 g single dose)
Study: 3846198
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with amoxicillin (250 mg three times daily for ten days)
Study: 31888504
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of remifentanil (group R)
Study: 28213783
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (doxorubicin, 5-fluorouracil/mitomycin, or epirubicin)
Study: 28213783
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (paclitaxel)
Study: 11132761
Drug: IV vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vitamin C 500 mg administered three times a week for three months
Study: 11132761
Drug: IV vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vitamin C 500 mg administered three times a week for the second three months
Study: 9060568
Drug: Sucralfate solution
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate solution
Study: 8453970
Drug: Amoxycillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (3 g)
Study: 8437256
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg)
Study: 30562268
Drug: i.v. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine (0.09-mg/kg total)
Study: 30562268
Drug: i.v. naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. naloxone (12-mg total)
Study: 29717840
Drug: TRUSC-guided administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRUSC-guided administration of traditional Chinese medicine, qd for 7 days before TURP
Study: 29717840
Drug: TRUSC-guided administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRUSC-guided administration of traditional Chinese medicine
Study: 12825062
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg diazepam and 0.015 mg/kg atropine sulfate
Study: 6661346
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AQ‐A 39
Study: 6661346
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg AQ‐A 39
Study: 26655084
Drug: NS11821 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS11821 (10 mg, 30 mg, 75 mg, 150 mg, 300 mg, 600 mg)
Study: 20814315
Drug: Low-dose risperidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose risperidone plus low-dose haloperidol (2 mg/d risperidone + 2 mg/d haloperidol)
Study: 20814315
Drug: Risperidone monotherapy
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone monotherapy (4 mg/d risperidone)
Study: 17905486
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (VAQTA) administered at 6 and 12 months of age
Study: 17905486
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine (HEXAVAC) administered at 2, 4, 6, and 12 months of age
Study: 15677625
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus ovarian suppression (either radiation-induced ovarian ablation or triptorelin for 3 years)
Study: 15677625
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone (control arm)
Study: 15677625
Drug: Ovarian suppression
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian suppression in patients <40 years of age with estrogen receptor-positive tumors
Study: 8624122
Drug: Besipirdine 5
Normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besipirdine 5 mg BID
Study: 8624122
Drug: Besipirdine 20
Normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besipirdine 20 mg BID
Study: 1923396
Drug: Topical medication
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medication containing tannic acid
Study: 30721296
Drug: EEG-guided anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG-guided anesthetic administration
Study: 26715763
Drug: Intradialytic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic resistance training using resistance elastic bands in a seated position during the first hour of haemodialysis treatment for 12, 24 or 36 weeks
Study: 19527468
Drug: Polaprezinc (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (34 mg/day)
Study: 3519285
Drug: 6 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of a 'CMF like' chemotherapy
Study: 3146465
Drug: Sodium fusidate
Normalized name: Sodium fusidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium fusidate ointment
Study: 25935145
Drug: Intravenous delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous delivery of flurbiprofen axetil, pentazocine and palonosetron via intravenous pump
Study: 22000847
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 150 mg single dose
Study: 22000847
Drug: Intra-vaginal clotrimazole
Normalized name: clotrimazole Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-vaginal clotrimazole 200 mg per day for six days
Study: 18374245
Drug: Environmental factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental factors (e.g., fewer culs-de-sac)
Study: 12839615
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate lotion (BDL)
Study: 10607678
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with autologous stem cell support (NMSG #5/94)
Study: 9252721
Drug: FEMP+PSK (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEMP+PSK (5-fluorouracil, cyclophosphamide, mitomycin C, predonisolone + 3.0 g of PSK)
Study: 9252721
Drug: NA (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA (no adjuvant therapy)
Study: 1556679
Drug: Sodium Meclofenamate
Normalized name: Meclofenamate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Meclofenamate (Meclomen) 100 mg po tid
Study: 1556679
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Sodium (Voltaren) 25 mg po tid
Study: 30342554
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) therapy, 16 mg per day (8 mg twice daily, days 1 to 4), halved every 3 days until 0.5 mg on day 19, stopped on day 20.
Study: 30342554
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) therapy
Study: 27232899
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide solution (H2O2) for 3 months
Study: 27232899
Drug: Biguanide‐preserved multipurpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biguanide‐preserved multipurpose solution (BMPS) for 3 months
Study: 27232899
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide solution (H2O2)
Study: 24405579
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group received access to a 'Rolling Store', nutrition education, and physical activity.
Study: 3156621
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy
Study: 12358368
Drug: Gentamicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (5 mg/kg)
Study: 12358368
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g)
Study: 3516257
Drug: Cetiedil at
Normalized name: cetiedil
DrugBank: Cetiedil (DB13753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetiedil at 0.4 mg/kg body weight
Study: 29432967
Drug: Timothy grass
Normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy grass SLIT‐T taken once daily for 4 months
Study: 29432967
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once daily for 4 months
Study: 29052340
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI) based ART
Study: 24050970
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone hydrochloride (3 doses of 50 mg each)
Study: 24050970
Drug: Aceclofenac (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (2 doses of 100 mg each)
Study: 24050970
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eperisone hydrochloride and aceclofenac
Study: 20091161
Drug: Ticagrelor 100-400
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 100-400 mg
Study: 12802748
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (1 g daily for 7 days; n=87)
Study: 12802748
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium penicillin G (1.5 million U every 6 h for 7 days; n=86)
Study: 12802748
Drug: Sodium penicillin
Normalized name: Penicillin G Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium penicillin G
Study: 10566924
Drug: 75 microg
Normalized name: Norgestrel 75 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg oral clonidine
Study: 10566924
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg oral clonidine
Study: 6723225
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium
Study: 21248199
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein and high PRAL diet (HPHP; total protein: 118 g/d; PRAL: 33 mEq/d)
Study: 21248199
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein and low PRAL diet (LPLP; total protein: 61 g/d; PRAL: ‐48 mEq/d)
Study: 9745413
Drug: 0.3 mg/kg.week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg.week recombinant human GH
Study: 8751029
Drug: Spirapril 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 1.5 mg
Study: 9493699
Drug: Spirapril 3
Normalized name: spirapril 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 3 mg
Study: 9493699
Drug: Spirapril 6
Normalized name: spirapril 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 6 mg
Study: 8751029
Drug: Enalapril 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5/10 mg
Study: 12053028
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral sildenafil citrate combined with self‐manual and visual sexual stimulation
Study: 12053028
Drug: Combined intracavernosal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intracavernosal injection of 60 mg of papaverine and sexual stimulation (CIS)
Study: 10444027
Drug: SC602 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC602 vaccine
Study: 7916183
Drug: RP 56976
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP 56976 (docetaxel) at 60 mg/m2
Study: 7916183
Drug: RP 56976
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP 56976 (docetaxel) at 70-90 mg/m2
Study: 2666293
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 40 mg tablet at night)